Salix Pharmaceuticals Previews PAINWeek® Presentation

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that one poster presentation describing the investigation of methylnaltrexone bromide will occur during The National Conference on Pain for Frontline Practitioners, or “PAINWeek”. PAINWeek is being held in Las Vegas, NV, Wednesday, Sept. 4 – Saturday, Sept. 7, 2013.

The poster presentation, by Nalamachu et al., is entitled, “Efficacy and Tolerability of Methylnaltrexone in Advanced Illness Patients with Opioid-Induced Constipation: A Responder Analysis.”

About RELISTOR ® (methylnaltrexone bromide)

RELISTOR Subcutaneous Injection was approved in the United States in 2008 for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. The use of RELISTOR beyond four months has not been studied. The drug is also approved for use in 58 countries worldwide, including the European Union, Canada, and Australia. In the 27 member states of the E.U., as well as Iceland, Norway and Liechtenstein, RELISTOR is approved for the treatment of opioid–induced constipation in advanced illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient. In Canada, the drug is approved for the treatment of opioid–induced constipation in patients with advanced illness, receiving palliative care. When response to laxatives has been insufficient, RELISTOR should be used as an adjunct therapy to induce a prompt bowel movement. Applications in additional countries are pending. RELISTOR is under license to Salix Pharmaceuticals and Ono Pharmaceutical from Progenics Pharmaceuticals.

For more information about RELISTOR, please visit  www.RELISTOR.com

Important Safety Information about RELISTOR

RELISTOR ® (methylnaltrexone bromide) Subcutaneous Injection is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their physician.

If you liked this article you might like

After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals Reunite

Biotech Hits an Inflection Point

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

2 Small Biopharma Stocks on the Move

2 Small Biopharma Stocks on the Move